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Immunotherapy has revolutionized cancer treatment. Immune-checkpoint inhibitors, on balance, showed a favorable effi-
cacy/toxicity profile with durable response in different cancer types. No predictive biomarker has been validated thus far to select
patients who would benefit from therapy. Among the candidate predictive biomarkers, mismatch repair status of the tumor is
currently one of the most promising. Indeed, tumors displaying mismatch repair deficiency or microsatellite instability showed
remarkable response to immunotherapy in clinical trials. This correlation has been first reported in colorectal cancers, but similar
results have been observed also in other cancer types.The possiblemechanism behind this correlationmay be the highermutational
load observed in mismatch repair deficient tumors, leading to neoantigens formation, recruitment of immune cells, and release
of proinflammatory factors in the microenvironment. These results support an approach to treatment based on assessment of
the genomic stability of the tumor besides its biologic characteristics and may change our therapeutic decision making process.
However, due to the small percentage of patients with tumors displayingmismatch repair deficiency, data from clinical trials should
not be considered definitive and need further confirmation.
1. Introduction
1.1. Immunotherapy and Immune-Checkpoint Inhibitors. The
immune system manipulation has been increasingly acquir-
ing a central role in cancer treatment; thanks to a deeper
understanding of immune system function in terms of anti-
tumor activity, several strategies targeting immune cells and
the microenvironment are under development. Undoubt-
edly, immune-checkpoint molecules are some of the best-
characterized and studied mechanism of interaction between
immune system and cancer.
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4) has been the first immune-checkpoint molecule to be
clinically targeted. Itsmain role is to regulate T cells activation
at the time of their initial response to the antigen, counter-
balancing the effect of T cell receptor (TCR)/CD3 activating
and CD28 costimulation signals. CTLA4 function is exerted
by binding to its ligand, CD80/CD86 (mainly expressed
by the antigen presenting cells, APCs), thus blocking the
costimulation signals of T cells and dampening the amplitude
of the response, resulting in immune suppression [1].
Similarly, a well-characterized immune-checkpointmole-
cule is the programmed cell death protein 1 (PD-1), expressed
by activated T cells, B cells, and natural killer (NK); PD-1
regulates the inflammatory responses mainly in the periph-
eral tissues, limiting collateral tissue damage in inflammatory
process resolution and autoimmunity phenomena [1, 2].
PD-1 activity is modulated by a specific set of ligands,
the programmed death-ligand 1 (PD-L1) and programmed
death-ligand 2 (PD-L2).
Inflammatory signals (i.e., interferon-𝛾, IFN𝛾) in the
microenvironment induce expression of PD-L1 and PD-L2.
PD-L1 is themost characterized PD-1 partner; it is commonly
expressed on T helper cells, myeloid derived suppressor cells
in the tumor microenvironment, and cancer cells, too.
The activity of PD-1/PD-L1 axis is immunosuppressive: in
particular, excessive induction of PD-1 pathway in the setting
of chronic antigen exposure as well as in cancer has been
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shown to induce an exhausted or anergic phenotype in T cells
[1, 2], thus impairing the antitumor activity of the immune
system.
Reverting immunosuppression promoted by immune-
checkpoint molecules like CTLA4, PD-1, and PD-L1 was
demonstrated to be an effective anticancer therapeutic strat-
egy. Immune-checkpoint inhibitors have shown a remarkable
clinical efficacy and durable responsewith a favorable toxicity
profile in a large number of solid and hematologic malignan-
cies [3], such asmelanoma [4, 5], lung cancer [NSCLC, [6, 7]],
bladder cancer [8], and renal cancer [RCC, [9]].
In particular, Ipilimumab, a CTLA4 blocking mono-
clonal antibody, has been FDA-approved for the treatment
of metastatic melanoma (MM), after showing an overall
survival advantage with a favorable toxicity profile. Another
anti-CTLA4, Tremelimumab, has been more recently devel-
oped and received orphan drug status for the treatment of
malignant mesothelioma. Similarly, FDA granted accelerated
approval of PD-1 inhibitors Nivolumab and Pembrolizumab
for the treatment of different tumors (as MM, advanced
NSCLC, head and neck squamous cell carcinoma, and clas-
sical Hodgkin’s lymphoma). On the other hand, anti-PD-
L1 antibodies Atezolizumab, Avelumab, and Durvalumab
obtained as well FDA accelerated approval in different solid
tumors, as advanced urothelial bladder cancer and Merkel
cells carcinoma. Many other anti-PD-1/PD-L1 molecules are
being developed with promising results in clinical trials.
1.2. Predictive Biomarkers. No predictive biomarkers have
been validated thus far to select patients who would mostly
benefit from immunotherapy, sparing nonresponders from
the risk of severe adverse events and saving costs.
PD-L1 protein expression by tumor and immune cells
has been investigated as a potential predictive biomarker
[10], but its correlation with immunotherapy efficacy is still
debated [11–13] and technical issues prevent its routine use
in clinical practice [6, 8]. In addition, PD-L1 expression
varies widely between tumor types and presents a signifi-
cant intrapatient heterogeneity with a frequent discordance
between primary tumors and metastases [14, 15]. Probably,
PD-1/PD-L1 expression reflects a dynamic process influenced
by multifactorial events like concomitant treatments, mainly
targeted therapies [16]. Other promising candidate predictive
biomarkers are currently under investigation [17], particu-
larly cells or molecules related to immune response in tumor
microenvironment such as tumor infiltrating lymphocytes
(TILs) [18], indoleamine 2,3-dioxygenase (IDO) [19], BCL-2
interacting mediator of cell death-Bim [20], and interferon-
gamma [21].
A different possible approach to predict immunotherapy
efficacy is to analyze the somatic mutational landscape of the
tumor, since a high mutational burden has been shown to
correlate with benefit from immunotherapy [22, 23]. How-
ever, whole exome sequencing is time and cost consuming
and currently not feasible routinely [24].
An increased rate of somaticmutations has been observed
particularly in mismatch repair (MMR) deficient tumors
that indeed have shown responsiveness to immunotherapy
independently of histologic and anatomic defined subtypes
[25]. Thus, MMR status of the tumor may represent a
potentially feasible and useful predictive biomarker; besides,
it has a well-known prognostic role. Although MMR defi-
cient cancers frequently show aggressive histological fea-
tures like high nuclear grade at microscopy, they have a
paradoxically favorable outcome. In a large series of young
colorectal cancer patients, microsatellite instability was asso-
ciated with a significant survival advantage independently
of all standard prognostic factors, including tumor stage
[26].
2. Mismatch Repair: Role and Implications
MMR system is a DNA integrity maintenance system. The
main role of MMR proteins is the correction of single base
nucleotide mismatches (insertions or deletions) generated
during DNA replication and recombination, thus maintain-
ing the genomic stability [27]. These proteins are responsible
for the corrections of mismatches that occurred during
meiosis and mitosis [28] and might have a potential role in
oxidative DNA damage repair [29] as well as in antibody
class-switch recombination [30].
The mechanism of MMR involves at least three different
processes: recognition, excision, and resynthesis. Recog-
nition of single base replication errors is performed by
the MutS𝛼 (MSH2-MSH6 heteroduplex) or MutS𝛽 (MSH2-
MSH3 heteroduplex), excision of the lagging strand from
the mismatch by one of the MutL complexes (mainly MutL𝛼
formed by MLH1/PMS2) recruited by MutS protein, and
resynthesis of the excised-DNA and ligation by DNA poly-
merase delta and DNA ligase I [31].
Loss of expression of one of the MMR proteins may
result from inherited germline defects (usually mutations) in
one of the mismatch repair genes; rarely both of inherited
alleles are mutated as in constitutional MMR deficiency
syndrome leading to cancer in early childhood called con-
stitutional mismatch repair deficiency [32]. More frequently,
only one mutated allele is inherited and loss of the other
allele occurs somatically, as in Lynch syndrome (LS), an
autosomal dominant condition that predisposes to cancer
development (particularly colorectal cancer (CRCs) and
ovarian and endometrial cancer) [28]. Alternatively, MMR
deficiency may be derived by either somatic mutation or
methylation of one of the MMR genes: sporadic MMR
deficient tumors are often the result of epigenetic silencing
of MLH1 promoter due to a hypermethylation mechanism
[33, 34].
Due to its role in genomic stability, MMR deficiency
leads to accumulation of somatic mutations [31]. Microsa-
tellites—repetitive short (1–6 base pairs) tandem DNA seq-
uences scattered throughout the whole genome—are partic-
ularly subject to copying errors when mismatch repair is
compromised. Therefore, it is possible to trace the MMR
deficiency by studying the microsatellites: when they are
demonstrated to be hypermutated (instable), MMR may be
deducted.
Recent evidence showed that tumors with microsatellite
instability due to MMR deficiency have different phenotype
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and histologic characteristics—and in some cases even a
different prognosis [35]—as compared to MMR proficient
tumors [36–38].
MMR status of the tumor may be assessed either by
immunohistochemistry (IHC) that tests loss of a MMR
protein or by PCR based assays for microsatellite instability
[39]. IHC and MSI testing are complementary as both have a
false negative rate of approximately 5–10%.
3. MMR Status as a Predictor of
Immunotherapy Efficacy: Clinical Data
The correlation between tumorMMR status and the outcome
in patients treated with immunotherapy has been initially
observed in CRCs treated with PD-1 blocker: only 1 of 33
patients with CRCs showed a response to immune-treatment,
despite remarkable efficacy of these anticancer agents in
other tumor subtypes [40, 41]. Since both MMR deficiency
and immunotherapy benefit are expected in a very small
fraction of CRCs patients, a possible correlation between
the two has been hypothesized and confirmed in a recent
phase II study [25]. A total of 41 patients with treatment
refractory progressive MMR deficient and proficient
metastatic CRCs were recruited, as well as a small proportion
of patients with MMR deficient cancers of other types
(cholangiocarcinoma, endometrial, small bowel, and gastric
cancer). The three different cohorts, consisting of 11, 21, and
9 patients, respectively, were treated with Pembrolizumab.
An immune related objective response rate (ORR)
of 40% was observed in MMR deficient CRCs compared
to a total lack of response in MMR proficient CRCs (ORR
0%), with a similar difference in progression free survival
(PFS) rate at 20 weeks between the two groups (78% versus
11%). Likewise, MMR deficient tumors other than CRCs
showed an ORR of 71% with a PFS of 67%. The difference
in survival of patients with MMR deficient and proficient
CCRs is independent from other prognostic factors, since
no significant differences in PFS between the two groups
were observed while receiving previous chemotherapy
regimens. Interestingly, all the six patients with MMR
deficient tumors not associated with Lynch syndrome had
an objective response, whereas only 27% of patients with
Lynch syndrome had a response. However—due to the small
sample size of the study population—these results require
further confirmation.
Numerous studies demonstrated that MMR status corre-
lates also with chemotherapy resistance, with MMR deficient
tumors being commonly resistant to methylating agents,
platinum compounds and fluoropyrimidines [42, 43]. A
possible explanation may involve DNA damage response
proteins (i.e., ataxia telangiectasia mutated (ATM) and ataxia
telangiectasia and Rad3-related protein (ATR)), recruited
by MMR proteins during treatment with DNA-damaging
agents. ATM/ATR, in turn, lead to cell cycle arrest, DNA
repair, or apoptosis through DNA damage checkpoint pro-
teins activation [43, 44]. MMR deficiency might alter this
mechanism and confer resistance to many chemotherapies
[45].
4. Exploiting Mismatch Repair Deficiency
as a Predictor of Immunotherapy Efficacy:
Biologic Rationale
Multiple possible mechanisms have been proposed to explain
the correlation between MMR deficiency and immune
response in some cancer types. It has been observed that
MMR deficiency is associated with a 10–100-fold-increased
rate of somaticmutations [46].The genomic analysis of whole
exome sequences of primary tumor samples from 15 patients
included in the study by Le and colleagues [25] revealed a
mean of 1782 somatic mutations per tumor inMMR deficient
neoplasms, compared to 73 mutations per tumor in MMR
proficient ones.
MMR deficiency may provide an upregulation of a large
number of genes involved in the immune response, as
proinflammatory cytokines and cytotoxic mediators through
a genome expression dysregulation, thus resulting in an
increased secretion of soluble mediators in the tumor
microenvironment with the subsequent activation of the PD-
1 pathway. This might justify the observation that MMR
deficient tumors are immunogenic [47].
In addition, somaticmutationsmay lead to the expression
of a high number of tumor neoantigens that could promote
the release of proinflammatory cytokines and elicit the
recruitment and activity of cytotoxic T cells [48, 49]. Indeed,
it has been described that MMR deficient tumors have a
dense infiltration of intraepithelial CD8+ T lymphocytes and
activated T helper cells.
Nevertheless, a recent study reported that the active anti-
tumor immune microenvironment may be counterbalanced
by the presence of immune-checkpoint ligands (i.e., PD-
1/PD-L1, CTLA4, LAG3, IDO1, TIM3,GITR, andTIGIT) that
favor immune escape, thus suggesting that TILs are mainly
directed at neoantigens [50]. This hypothesis appears to be
confirmed by clinical data, as NSCLC and MM—cancers
known to have a high mutational load as a result to exposure
to cigarette smoking and UVA radiation, respectively—are
among the tumor types most responsive to PD-1 blockade.
Moreover, patients affected by NSCLCwith a high number of
somatic mutations have significantly better clinical outcomes
compared to patients with lessmutated tumors [51]. A similar
correlation has been observed for MM patients treated with
anti-CTLA-4 therapy [52]. Since neoantigens are frequently
different between patients and a single mutation cannot
predict response to immunotherapy, the candidate predictive
factor is the presence of high mutational load and the
consequent recruitment of T cells in the microenvironment
[53].
A recent study evaluated PD-L1 expression in MMR
deficient endometrial tumors, either Lynch syndrome asso-
ciated or sporadic tumors (with MLH1 hypermethylation),
and showed a significant higher PD-L1 expression compared
to the MMR proficient counterpart [54]. Likewise, a case of
MMR deficient sporadic high-grade urothelial carcinoma of
the renal pelvis treated with immunotherapy was reported:
the patient experienced a prolonged complete remission in
twomonths [55]. Besides sporadic case reports, the landscape
of microsatellite instability across different cancer subtypes
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is still poorly understood. A recent study examined 5.930
cancer exomes from 18 cancer types at more than 200.000
microsatellite loci, analyzing also cancer types for which MSI
status has not been previously tested in clinical practice.
The average number of unstable sites varied considerably by
cancer type, ranging from aminimum of 765 unstable sites in
thyroid carcinomas, to a maximum of 2.315 in colon cancers
[56]. Endometrial, colon, and gastric cancer were confirmed
to have the highest proportion of microsatellite instability;
however most cancer types examined (14 of 18) included
one or more representatives with microsatellite instability,
suggesting that this could be a generalized, continuous rather
than discrete, cancer phenotype. This heterogeneity adds
further complexity to the scenario of potential predictive
biomarkers of immunotherapy response. Interestingly, this
analysis identified loci more likely to be unstable in specific
cancer types, resulting in specific signatures in cancer-
associated genes, suggesting that instability patterns may
reflect selective pressures and can potentially identify novel
cancer drivers [56].
5. Conclusion
Data from recent clinical studies suggest that immunother-
apy with immune-checkpoint inhibitors may represent a
promising therapeutic strategy for patients with MMR defi-
cient tumors, independently of subtype. The proportion
of candidate patients, however, is relatively small, because
MMR deficiency has been observed only in about 4%
of metastatic CRCs, 11% of ovarian carcinomas, 18% of
endometrial cancers, and 1% of pancreatic cancers [25, 57].
A few reports showed promising results also in cancers
not usually treated with immunotherapy, thus suggesting
that screening for MMR deficiency should be potentially
offered to all patients with advanced disease, independently
from histology. Accordingly, some current ongoing studies
are exploring the potential predictive role of MMR status,
as summarized in Table 1. Most importantly, these results
support an approach to treatment based on genetic sta-
tus of tumor regardless of cancer subtype. Eventually, a
better understanding of pathologic and genomic features
of MMR deficient tumors may allow the identification of
other biomarkers (such as TILs, immune-checkpoint pro-
teins, and genomic mutations) potentially useful in clinical
routine practice to predict response to immunotherapy or
as surrogate markers of early response to therapy [17].
Indeed, microsatellite instability alone may not be suffi-
cient to predict response to immune-checkpoint inhibitors,
as, for example, not all tumor neoantigens may bind the
major histocompatibility complex (MHC) class I. Additional
immune-regulatory mechanisms may have a role as a con-
tributor of anti-PD-1/PD-L1 response, as T cell absence and
genetic/epigenetic alterations [58]. Accordingly, it has been
demonstrated that PI3K/PTEN/AKT pathway hyperactivity
may dampen antitumor immune activation when PTEN-
null tumors are exposed to an immune-checkpoint inhibitor,
thus suggesting a specific genetic regulatory mechanism
[59].
A global concept has recently been summarized by Chen
andMellman [60] in the definition of an “immune set-point”
as a global immune activation status potentially predictive of
response to immune therapies as well as a tool to guide the
choice of different strategies of treatment.
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